S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums

Biogen (BIIB) Stock Forecast, Price & News

$300.20
-2.21 (-0.73%)
(As of 06/2/2023 ET)
Compare
Today's Range
$297.68
$303.17
50-Day Range
$269.98
$318.06
52-Week Range
$188.54
$319.74
Volume
817,147 shs
Average Volume
800,069 shs
Market Capitalization
$43.45 billion
P/E Ratio
13.94
Dividend Yield
N/A
Price Target
$328.92

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
9.6% Upside
$328.92 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.42mentions of Biogen in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$982,911 Sold Last Quarter
Proj. Earnings Growth
6.04%
From $15.40 to $16.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

328th out of 983 stocks

Biological Products, Except Diagnostic Industry

49th out of 164 stocks


BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (BIIB)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Biogen (NASDAQ:BIIB) PT Raised to $360.00
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Medicare Plans to Cover Alzheimer’s Drugs
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Goldman Sachs Remains a Buy on Biogen (BIIB)
Biogen (BIIB) Receives a Buy from Mizuho Securities
Analyst Ratings for Biogen
See More Headlines

BIIB Price History

BIIB Company Calendar

Last Earnings
4/25/2023
Today
6/04/2023
Next Earnings (Estimated)
7/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$328.92
High Stock Price Forecast
$371.00
Low Stock Price Forecast
$263.00
Forecasted Upside/Downside
+9.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
26 Analysts

Profitability

Net Income
$3.05 billion
Pretax Margin
36.45%

Debt

Sales & Book Value

Annual Sales
$10.10 billion
Cash Flow
$21.35 per share
Book Value
$95.25 per share

Miscellaneous

Free Float
143,801,000
Market Cap
$43.45 billion
Optionable
Optionable
Beta
0.18

Social Links


Key Executives

  • Christopher A. Viehbacher
    President, Chief Executive Officer & Director
  • Nicole Murphy
    Head-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Executive VP, Head-Research & Development













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

26 equities research analysts have issued twelve-month target prices for Biogen's stock. Their BIIB share price forecasts range from $263.00 to $371.00. On average, they anticipate the company's share price to reach $328.92 in the next year. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the start of the year. Since then, BIIB shares have increased by 8.4% and is now trading at $300.20.
View the best growth stocks for 2023 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 30.4% from the April 30th total of 2,270,000 shares. Based on an average daily volume of 905,900 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the company's shares are sold short.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its earnings results on Tuesday, April, 25th. The biotechnology company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.25 by $0.15. The biotechnology company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 30.99% and a trailing twelve-month return on equity of 19.60%. The company's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.62 EPS.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $15.00-$16.00 for the period, compared to the consensus estimate of $15.48. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.66%), State Street Corp (4.67%), Wellington Management Group LLP (3.77%), Geode Capital Management LLC (2.14%), Envestnet Asset Management Inc. (1.77%) and Price T Rowe Associates Inc. MD (1.44%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $300.20.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $43.45 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $21.54 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -